Cellular Energy – Ayurved Healing

Mitochondrial Health and Rasayana: How Rejuvenative Herbs Protect Cellular Power Plants

Dr. Meera Iyer — Wed, 10 Jun 2026 09:00:00 +0000

Mitochondria are membrane-bound organelles that generate much of the ATP used by human cells through oxidative phosphorylation. They also participate in calcium handling, redox signaling and programmed cell death. These functions make mitochondrial biology relevant to energy metabolism, muscle performance, neurological function and many diseases. However, Ayurveda’s classical texts do not describe mitochondria, ATP, Coenzyme Q10 or molecular pathways such as PGC-1alpha.

Rasayana should therefore not be presented as an ancient name for mitochondrial medicine, and Ojas should not be equated with ATP. Rasayana is a classical Ayurvedic branch and therapeutic approach concerned with preserving health, function and longevity; its scope is broader than any organelle or supplement. Modern research can test whether particular Rasayana substances influence mitochondrial pathways, but that is a contemporary research bridge, not proof that the two systems are identical.

What Mitochondrial Health Means Clinically

In cells that contain mitochondria, the electron-transport chain transfers electrons through respiratory complexes and uses a proton gradient to make ATP. Coenzyme Q10 is a mobile lipid-soluble carrier that receives electrons from Complexes I and II and transfers them toward Complex III. Mitochondria also generate reactive oxygen species: excessive amounts may contribute to damage, while controlled amounts serve normal signaling roles.

Primary mitochondrial diseases are diverse, often genetic disorders whose manifestations vary between people and organs. Fatigue, exercise intolerance, weakness and cognitive complaints may occur, but none is specific enough to diagnose mitochondrial disease. Persistent or progressive symptoms require clinical assessment rather than self-diagnosis as “low Ojas” or “mitochondrial fatigue.”

Regular physical activity has much stronger human evidence for mitochondrial adaptation than any Ayurvedic herb. Endurance and resistance exercise can stimulate mitochondrial remodeling, including PGC-1alpha-related signaling, while improving cardiovascular and muscular fitness. Sleep, adequate nutrition and treatment of proven deficiencies are foundational; supplements should not replace investigation of common causes of fatigue.

Rasayana Herbs and the Actual Mitochondrial Evidence

The table separates human outcomes from mechanistic evidence. A result in cells, flies, mice or rats does not establish a clinically meaningful mitochondrial effect in people. Botanical identity also matters: the Ayurvedic Pharmacopoeia definition cited by the Ministry of AYUSH identifies Ashwagandha as the dried mature root of Withania somnifera, not the leaf.

Substance	Verified Evidence	Important Limit
Ashwagandha root (Withania somnifera)	Small, short human trials suggest possible benefits for stress, sleep and selected physical-performance measures. Cell and animal studies have examined mitochondrial energetics and PGC-1alpha-related signaling.	No convincing human trial has shown that Ashwagandha increases mitochondrial number or treats mitochondrial disease. Preparations and populations vary.
Purified Shilajit	A 2009 preclinical paper studied Shilajit-derived dibenzo-alpha-pyrones with CoQ10 in isolated systems and rodents. A separate 2019 trial in 63 active men studied strength retention after fatigue.	The first was not a human ATP trial; the second did not combine Shilajit with CoQ10 or measure mitochondrial biogenesis. Unpurified material may contain contaminants.
Bacopa (Bacopa monnieri)	Human trials and a meta-analysis suggest effects on selected cognitive-test outcomes. Mitochondrial and antioxidant findings are mainly preclinical.	Cognitive findings do not prove a mitochondrial mechanism. “Brahmi” may also denote Centella asiatica, so the botanical name must be stated.
Amalaki (Phyllanthus emblica, syn. Emblica officinalis)	Amalaki is used in the Rasayana tradition. A human retinal-cell laboratory model reported effects on oxidative stress, membrane potential and PGC-1alpha expression.	The cell model does not prove clinical protection of mitochondrial DNA, preservation of all respiratory complexes or superiority to synthetic vitamin C.
Guduchi (Tinospora cordifolia)	Animal research, including a rotenone-induced mouse model, has examined oxidative stress and mitochondrial dysfunction.	No human mitochondrial benefit is established. Case series and reviews link some Tinospora cordifolia products with clinically apparent liver injury.

Shilajit and the CoQ10 Question

CoQ10 cycles between oxidized and reduced forms during electron transport; calling only ubiquinol the “active” form oversimplifies this redox cycle. The frequently repeated Shilajit claim comes from a 2009 paper in Pharmacologyonline, not the Journal of Agricultural and Food Chemistry. Its experiments used isolated dibenzo-alpha-pyrones, mitochondrial preparations and small groups of rodents. One rat experiment found higher tissue CoQ with a dibenzo-alpha-pyrone plus CoQ10 than with CoQ10 alone, but it did not demonstrate a 29% improvement in human electron-transfer efficiency, ATP, fatigue or exercise capacity.

The cited 2019 human study did not test a Shilajit-CoQ10 combination. It randomized 63 recreationally active men to placebo or purified Shilajit for eight weeks and assessed strength after fatigue. The higher-dose group retained maximal voluntary isometric contraction better after a fatiguing protocol, while other findings depended on subgroup analysis. This is preliminary performance evidence, not proof of mitochondrial rejuvenation.

There is therefore no verified basis for telling everyone who takes CoQ10 to add Shilajit or for prescribing a universal dose here. Anyone considering it should consult a qualified healthcare professional and use only purified material with independent, batch-specific contaminant testing. Pregnancy, chronic disease, medicines and unexplained fatigue all require individualized advice.

PGC-1alpha and Mitochondrial Biogenesis

PGC-1alpha is an important transcriptional coactivator in mitochondrial biogenesis and energy metabolism, but it is not a solitary on-off switch. Exercise, cellular energy status and multiple signaling networks regulate mitochondrial content and function. Human exercise studies support PGC-1alpha-related adaptation, although responses vary by training status, exercise type, tissue and measurement timing.

Later cell and animal studies have explored Ashwagandha-related changes in mitochondrial function and PGC-1alpha-associated pathways. They generate hypotheses but do not establish mitochondrial biogenesis in patients or clinical synergy between Ashwagandha and exercise.

A Safer Mitochondria-Supportive Rasayana Framework

A responsible Rasayana plan begins with the person, not a five-supplement stack. Ayurvedic care is individualized, while modern care must also consider diagnosis, laboratory findings, medicines, pregnancy and organ function. The following framework is safer than fixed morning and bedtime doses.

Investigate persistent symptoms: unexplained fatigue, weakness, neurological change, exercise intolerance or multisystem symptoms should be assessed by a healthcare provider.
Use movement as the foundation: combine aerobic activity with progressive resistance work at a level appropriate to health and fitness. Begin gradually and seek clearance when symptoms or heart disease make exercise uncertain.
Correct documented deficiencies: CoQ10, magnesium or B vitamins should not be prescribed merely because fatigue is present. History, diet, medicines and testing determine whether supplementation is appropriate.
Choose one defined Ayurvedic intervention when indicated: a qualified practitioner can select the botanical, plant part, preparation and duration. This is preferable to taking Ashwagandha, Shilajit, Bacopa, Amalaki and Guduchi together.
Monitor quality and safety: use traceable products with appropriate testing, disclose supplements to clinicians and stop promptly if jaundice, dark urine, severe itching or another concerning reaction occurs.

Even when Amalaki is used in food form, a spoonful of powder has not been shown to protect mitochondrial DNA within an hour or produce measurable mitochondrial improvement in 30 days. Ashwagandha may be unsuitable during pregnancy and can interact with medicines or affect thyroid function; rare liver injury has also been reported. Guduchi deserves particular caution because liver-injury reports contradict the assumption that every traditional herb is harmless.

Mitochondria, Aging and the Limits of the Analogy

Denham Harman proposed the free-radical theory of aging in 1956 and later emphasized mitochondria in a 1972 paper. Mitochondrial damage and altered bioenergetics remain important research areas, but the idea that mitochondrial ROS is the single primary cause of aging is no longer sufficient. Reactive oxygen species can also act as signals, mitochondrial DNA has repair systems, and aging involves many interacting processes.

Rasayana can remain a valuable traditional framework for preserving function, routine, nourishment and resilience. What cannot yet be claimed is that Amalaki clinically protects human mitochondrial DNA, Shilajit restores the electron-transport chain, Ashwagandha reverses glucocorticoid uncoupling, or Bacopa prevents neuronal mitochondrial aging in people. Those conclusions go beyond the largely preclinical evidence.

For related reading, see our Ashwagandha dosage guide, Shilajit composition guide and Amla/Amalaki guide. Supplement claims should always be distinguished by whether they come from human outcomes, surrogate biomarkers or preclinical experiments.

This article is educational and does not diagnose or treat mitochondrial disease, fatigue or any chronic condition. Most herb-specific mitochondrial findings discussed here come from laboratory or animal studies. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before using medicinal doses of herbs or combining them with CoQ10, medicines or other supplements. Seek medical evaluation for persistent, progressive or multisystem symptoms. Shilajit should only be used in purified, independently tested form.

Actionable tip: Begin with regular, tolerable physical activity, consistent sleep and balanced meals rather than a multi-herb “mitochondrial stack.” Build aerobic and resistance activity gradually according to your health and capacity, and investigate unexplained fatigue before adding supplements.

References

AMPK Activation and Ayurvedic Metabolism Herbs: Where Cellular Energy Science Meets Tradition

Dr. Meera Iyer — Fri, 29 May 2026 09:00:00 +0000

AMP-activated protein kinase (AMPK) is a central regulator of cellular energy balance and an important research target in metabolic disease. When cellular energy becomes limited, AMPK helps restore balance by restraining energy-consuming biosynthesis and promoting pathways that generate or conserve ATP. In skeletal muscle and other tissues, its downstream effects can include increased glucose transport, greater fatty-acid oxidation, regulation of autophagy, and longer-term changes in mitochondrial capacity.

Exercise can activate AMPK in working muscle, and fasting or other forms of energetic stress can engage the pathway in a tissue- and context-dependent manner. Metformin also influences AMPK, but it is inaccurate to say that the medicine works only, or even conclusively “primarily,” through AMPK. Current reviews describe several AMPK-dependent and AMPK-independent mechanisms, including effects on mitochondrial respiration, hepatic glucose production, lysosomal signalling, and cellular redox balance.

Some plants used in Ayurveda contain compounds that influence AMPK in cells or animals. That does not mean the classical texts described a kinase, that every preparation of the plant produces the same molecular effect, or that a preclinical mechanism proves clinical efficacy. The useful question is narrower: what AMPK evidence exists, what has actually been shown in people, and what does the Ayurvedic Pharmacopoeia of India say about the traditional drug?

AMPK: What the Pathway Actually Does

AMPK is a serine/threonine protein kinase complex that responds to changes in cellular energy status, including increases in AMP:ATP or ADP:ATP ratios. Activation also depends on upstream kinases and cellular location, so AMPK should not be treated as a single universal “on switch.” Its effects vary by tissue, duration, nutritional state, and the particular compound being studied.

It inhibits several ATP-consuming anabolic processes, including fatty-acid and cholesterol synthesis and, under appropriate conditions, protein synthesis.
It promotes ATP-generating processes such as fatty-acid oxidation and can increase glucose transport in contracting skeletal muscle.
It participates in the regulation of autophagy and mitochondrial quality control.
It can support GLUT4 translocation in muscle, but this should not be generalized to every cell type or equated with a guaranteed fall in blood glucose.
Its relationship with hepatic gluconeogenesis and whole-body glycaemia is complex; AMPK activation is one mechanism among several, not a complete explanation for every metabolic effect.

For this reason, “activates AMPK” is a mechanistic observation, not a therapeutic verdict. A compound may activate AMPK only at concentrations that are difficult to reach in humans, may act through additional pathways, or may have poor absorption and significant interactions. Clinical outcomes such as HbA1c, adverse effects, and medication requirements remain more important than a laboratory pathway label.

Herb 1: Meshashringi or Gudmar (Gymnema sylvestre)

The Ayurvedic Pharmacopoeia of India identifies the dried leaf as Meṣaśṛṅgī and lists Madhunāśinī and Ajāśṛṅgī as Sanskrit synonyms; Gudmar is a Hindi name. The leaf monograph gives tikta and kaṣāya rasa, laghu and rukṣa guna, uṣṇa virya, and kaṭu vipaka. Its listed actions include dīpana, kaphahara, and vātahara, and its therapeutic uses include prameha.

Gymnemic acids are triterpenoid saponins associated with the plant’s well-demonstrated ability to suppress sweet taste temporarily. Human experiments have shown reduced oral sweet sensation after gymnemic-acid preparations. This sensory effect is real, but it should not be presented as proof that the herb treats diabetes or that the same receptor mechanism necessarily blocks clinically meaningful amounts of intestinal glucose.

The AMPK evidence is preclinical. A 2019 study of gymnemic acid in a rat model of type 2 diabetes reported changes involving PI3K/AKT- and AMPK-related pathways. That supports further investigation, but it does not establish an LKB1 mechanism in humans.

Human studies of Gymnema sylvestre have reported possible improvements in glucose-related outcomes, but preparations, doses, study designs, and quality vary. The API lists 3–6 g for the crude leaf drug, but that traditional monograph dose is not interchangeable with milligrams of a standardized extract. No single extract dose should be called universally “evidence based.”

Herb 2: Daruharidra (Berberis aristata) and Berberine

Daruharidra and isolated berberine must be distinguished. The API monograph defines Daruharidra as the dried stem of Berberis aristata and identifies its constituents broadly as alkaloids. It records tikta rasa, rukṣa guna, and uṣṇa virya; the monograph does not assign a vipaka. Listed therapeutic uses include medoroga, kapharoga, and meha, with 5–10 ml of the drug in decoction form. This does not mean that a Daruharidra decoction delivers the same exposure as 500 mg of purified berberine hydrochloride.

Berberine has stronger AMPK evidence than the other substances discussed here. In cell and rodent studies it can inhibit mitochondrial respiratory complex I, alter cellular energy status, and activate AMPK. However, studies also show that some of berberine’s effects on glucose utilization can occur when AMPK signalling is blocked. It is therefore more accurate to describe AMPK as one component of a multi-pathway mechanism, not to call berberine a natural equivalent of metformin.

The often-cited 2008 comparison with metformin was a small pilot study in Metabolism. In one part of that study, 36 newly diagnosed adults were randomized to berberine or metformin for 13 weeks; a second group received berberine as add-on treatment. The findings were encouraging, but the sample was small and do not establish therapeutic equivalence. A separate 116-participant 2008 trial compared berberine with placebo in people who had type 2 diabetes and dyslipidaemia.

Reviews suggest that berberine may improve glycaemic and lipid outcomes as an adjunct, but heterogeneity and study quality limit certainty. Gastrointestinal effects such as nausea, diarrhoea, bloating, and constipation are common. Human pharmacokinetic research also indicates potential inhibition of CYP2D6, CYP2C9, and CYP3A4 after repeated administration. Berberine can interact with medicines, should not be used during pregnancy or breastfeeding, and should not be given to infants. A dose used in a trial is not an automatic self-treatment recommendation.

Herb 3: Shilajit — AMPK Activation Not Established

Shilajit should not be placed in a table of proven AMPK activators. Published animal work has explored mitochondrial function and fatigue, and chemical reviews discuss fulvic substances and dibenzo-α-pyrone-related constituents. However, direct human evidence that shilajit activates, “normalizes,” or therapeutically regulates AMPK in metabolic disease was not found. Claims that fulvic acid enhances CoQ10 specifically at complex I, or that shilajit corrects insulin resistance by normalizing AMPK, go beyond the available evidence.

A 2025 computational docking paper proposed possible AMPK-binding compounds from shilajit, but docking predicts molecular fit; it does not demonstrate absorption, target engagement, efficacy, or safety in humans. Form, extraction, purification, and batch composition vary too much for appearance alone to establish quality.

The defensible safety point is quality control. Shilajit is a complex mineral-organic material, and reviews have documented substantial variability in elemental composition, including concern about toxic metals in some samples. Anyone using it should choose a purified product with a batch-specific certificate from a competent independent laboratory. Shilajit should not be presented as a substitute for diabetes treatment or as a confirmed AMPK therapy.

Herb 4: Karela or Karavallaka (Momordica charantia)

The API identifies the fresh fruit of Momordica charantia as Kāravallaka and records kaṭu and tikta rasa, laghu guna, uṣṇa virya, and kaṭu vipaka. Its listed actions include dīpana, kaphahara, and vātahara, and its therapeutic uses include prameha. The monograph gives 10–15 ml of fresh juice. This is a pharmacopoeial traditional dose, not proof of efficacy for type 2 diabetes.

Preclinical AMPK findings are credible but more specific. A 2008 study isolated cucurbitane triterpenoids from bitter melon and linked their metabolic effects to AMPK activation in cell systems and mice. Later work found that bitter-melon triterpenoids could activate AMPK through CaMKKβ-associated signalling and increase GLUT4 translocation in vitro. These studies did not establish that charantin acts through an LKB1 pathway, nor that charantin, vicine, and polypeptide-P are all proven AMPK activators.

Research has described insulin-like peptides and separate insulin-receptor-binding peptides from bitter melon, but these should not be conflated without compound-specific evidence. Whole fruit, juice, powdered plant, isolated triterpenoids, and peptide fractions are pharmacologically different preparations.

Clinical evidence remains uncertain. A Cochrane review found only four trials of generally low quality and concluded that the evidence did not justify using bitter melon as a treatment for type 2 diabetes. Later reviews have reported possible glucose-lowering effects, but results are inconsistent and certainty remains limited. Karela can be eaten as food, but concentrated juice or extracts should not be assumed to be harmless or equivalent to culinary use.

What the Evidence Supports — and What It Does Not

The four substances do not belong in one equal-strength category. Berberine has the clearest mechanistic and human metabolic literature, although it has important limitations and interaction risks. Gymnema and bitter melon have preclinical AMPK findings and some human glycaemic research, but neither has a sufficiently standardized evidence base for confident stand-alone treatment claims. Shilajit has no established human AMPK role.

Substance	Verified AMPK evidence	Human metabolic evidence	Ayurvedic/API position
Meshashringi/Gudmar	Preclinical pathway findings; no verified human AMPK activation study	Suggestive but heterogeneous clinical literature	API leaf monograph includes prameha; tikta-kaṣāya, laghu-rukṣa, uṣṇa, kaṭu vipaka
Daruharidra/berberine	Berberine activates AMPK in experimental models, with AMPK-independent effects also reported	Possible adjunctive benefit; evidence quality and formulations vary	API Daruharidra stem monograph includes medoroga, kapharoga, and meha; it is not identical to isolated berberine
Shilajit	No established direct human AMPK evidence	Insufficient for a diabetes or metabolic-syndrome claim	Traditional use does not validate the proposed AMPK/CoQ10 mechanism
Karela/Karavallaka	Cucurbitane triterpenoids activate AMPK in cells and animals	Inconsistent, generally low-certainty evidence	API fresh-fruit monograph includes prameha; kaṭu-tikta, laghu, uṣṇa, kaṭu vipaka

No clinical trial was found demonstrating that Gudmar plus Karela or berberine plus shilajit produces the specific “synergistic AMPK activation.” Combining glucose-lowering herbs may increase adverse effects or complicate medication adjustment. Traditional formulation logic, preclinical pathway overlap, and proven clinical synergy are three different levels of evidence and should not be treated as interchangeable.

Safety Considerations and Drug Interactions

These products can have biologic effects, and “natural” does not mean interaction-free. The greater the number of glucose-lowering medicines and supplements used together, the more important supervised monitoring becomes. Product identity also matters: a culinary vegetable, crude pharmacopoeial drug, concentrated extract, and isolated alkaloid are not dose-equivalent.

Diabetes medicines: Gymnema, bitter melon, and berberine may add to glucose-lowering treatment. People using insulin, sulfonylureas, or other diabetes medicines should not add them without clinician guidance and an agreed monitoring plan.
Berberine: Interaction potential extends beyond CYP3A4 and may involve CYP2D6, CYP2C9, transporters, and clinically important medicines such as immunosuppressants. Pregnancy, breastfeeding, and infancy are contraindicated.
Bitter melon: Concentrated preparations may lower glucose and can cause gastrointestinal effects. Evidence is insufficient to replace standard diabetes therapy.
Gymnema: Extract standardization varies, and rare liver injury has been reported. Stop use and seek medical care for jaundice, dark urine, severe fatigue, or persistent nausea.
Shilajit: Use only purified, batch-tested material with documented limits for toxic elements; resin appearance or solubility is not a substitute for laboratory testing.

For broader context, see Herb-Drug Interactions: A Pharmacologist Safety Guide and From Clinic to Lab: How Reverse Pharmacology Is Proving Ayurveda.

This article is educational and does not diagnose or treat diabetes. Do not start, stop, or change insulin, metformin, sulfonylureas, or any other prescription medicine because of an herbal product. Anyone with prediabetes, type 2 diabetes, kidney or liver disease, pregnancy, breastfeeding, or multiple medicines should consult a qualified Ayurvedic practitioner and the prescribing healthcare professional before using concentrated herbs or extracts. Regular glucose monitoring should be directed by the treating clinician.

Key References

Hardie DG. AMPK as a cellular energy sensor and regulator of metabolism.
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin.
Li Y et al. Gymnemic acid in a rat model of type 2 diabetes.
Turner N et al. Berberine, mitochondrial complex I, and AMPK activation.
Yin J et al. Pilot clinical study of berberine in type 2 diabetes.
Tan MJ et al. Bitter-melon triterpenoids and AMPK activation.
Ooi CP et al. Cochrane review of Momordica charantia for type 2 diabetes.
The Ayurvedic Pharmacopoeia of India, Part I, Volumes II and V.

References

Mitochondrial Health Through Ayurvedic Rasayana: What Cell Energy Research Shows

Dr. Meera Iyer — Tue, 12 May 2026 09:00:00 +0000

When I first encountered the classical descriptions of Rasayana, I read them through the lens of pharmacognosy. Claims of longevity, memory, intelligence, freedom from illness, youthful qualities, strength, lustre, and clarity seemed too broad to translate into a single modern mechanism. The often-quoted list belongs to the Charaka Samhita, Chikitsa Sthana 1, not to a laboratory description of mitochondria or an exact quotation from the Ashtanga Hridaya.

Modern mitochondrial research nevertheless offers a legitimate area for comparison. Mitochondria participate in energy production, redox signalling, apoptosis, inflammation, and metabolic adaptation. That does not prove that classical authors were describing mitochondria, but it does justify asking whether particular Rasayana materials influence mitochondrial or oxidative-stress pathways in experimental models.

Some studies report effects on respiratory-chain enzymes, membrane potential, antioxidant systems, muscle adaptation, or exercise performance. Most are animal, cell, or small human studies, and several commonly repeated claims—direct CoQ10 cycling by shilajit, PGC-1α activation by multiple herbs, proven mitophagy from Guduchi, or mitochondrial rejuvenation in humans—are not established.

The Classical Rasayana Framework

Rasayana is counted among Ayurveda’s eight branches. In the opening chapter of the Charaka Samhita’s treatment section, it is described as a means of attaining excellent qualities of rasa and the succeeding dhatus. The passage associates Rasayana with longevity, memory, intelligence, freedom from disorder, youthfulness, strength, complexion, voice, and brilliance. These are classical therapeutic aims, not validated modern clinical outcomes.

Rasa dhatu should not be reduced to “blood plasma,” and the succession of seven dhatus should not be rewritten as a modern cellular nutrition pathway. Ayurveda uses its own functional language of agni, dosha, dhatu, srotas, suitability, preparation, and conduct. Biomedical concepts such as oxidative phosphorylation, mitochondrial DNA, and autophagy arise from a different explanatory system. Comparison may generate research questions, but identity claims obscure both traditions.

Charaka also makes Rasayana more than a supplement programme. The chapter describes indoor and outdoor modes of administration, emphasises preparation of the recipient, and states that prescribed methods succeed in a person whose body and mind have been properly prepared. Achara Rasayana adds truthfulness, nonviolence, calmness, cleanliness, measured sleep and waking, compassion, self-control, and respectful conduct. A four-capsule “mitochondrial stack” is not a classical Rasayana course.

Where Mitochondria Fit—and Where They Do Not

Mitochondria generate most cellular ATP through oxidative phosphorylation, but they are not merely batteries. They continually fuse, divide, alter their number, communicate with the nucleus, and are removed through quality-control pathways that include mitophagy. Ageing research examines impaired bioenergetics, dynamics, redox balance, quality control, inflammation, and cellular senescence. Mitochondrial dysfunction is one hallmark among several, not the single cause of ageing.

The older statement that mitochondrial DNA is “unprotected” and has almost no repair is also inaccurate. Mitochondrial DNA is packaged in nucleoids with proteins including mitochondrial transcription factor A, and mitochondria possess DNA-repair pathways. Mutations and damage can still accumulate, but the biology is more complex than a simple contrast between protected nuclear DNA and unprotected mitochondrial DNA.

Shilajit: Preclinical Mitochondrial Evidence, Limited Human Proof

Shilajatu or shilajit is a complex mineral-organic exudate, not a plant species; therefore “Asphaltum punjabianum” should not be treated as a modern botanical name. Charaka includes properly processed shilajatu in the Rasayana chapter and gives detailed processing and administration instructions. Neither the classical passage nor modern evidence establishes reversal of biological ageing in humans.

The most directly relevant experiment is a 2012 rat study of a processed, chemically standardised shilajit preparation in a forced-swim model of chronic fatigue. Investigators measured respiratory-chain complex activities and mitochondrial membrane potential in the prefrontal cortex and reported protection against stress-associated changes. This animal study cannot be converted directly into a human dose or longevity claim.

Human research is more indirect. A 2016 study reported skeletal-muscle gene-expression changes after oral shilajit in overweight or class-I obese adults. A 2019 randomised trial in recreationally active men tested 250 or 500 mg daily for eight weeks and measured fatigue-related strength loss and serum hydroxyproline, not ATP production, mitochondrial copy number, CoQ10 cycling, or PGC-1α. A cited fulvic-acid study was published in 2011 and affected tau aggregation in vitro; it was not a 2009 mitochondrial trial or an Alzheimer’s treatment trial.

Shilajit Quality and Dose Context

No single “standard dose” applies to every resin, powder, or extract because composition and standardisation differ. Published human studies can show what was tested, but they do not create a universal prescription. Classical shodhana and modern identity, contaminant, and batch testing answer different quality questions.

Evidence source	Material and amount studied	What was actually measured
2012 animal experiment	Standardised processed shilajit; weight-based rat doses	Brain respiratory-chain enzymes, membrane potential, oxidative-stress markers, and behaviour
2016 human transcriptome study	Oral standardised shilajit in overweight/class-I obese adults	Skeletal-muscle gene-expression responses
2019 human trial	250 or 500 mg daily for eight weeks	Fatigue-related muscular strength and serum hydroxyproline

Shilajit should be purchased only from a reputable source providing identity, microbial, pesticide, and heavy-metal testing. “Natural” or “classically purified” on a label is not a substitute for a certificate tied to the finished batch. Unidentified raw material and products making drug-like anti-ageing claims should not be self-administered.

Amalaki: Antioxidant Evidence Is Not Mitochondrial Rejuvenation

Āmalakī fruit has a prominent place in Charaka’s Rasayana formulations. The Ayurvedic Pharmacopoeia of India monograph lists it as Emblica officinalis Gaertn.; biomedical literature also commonly uses Phyllanthus emblica L. Its fruits contain tannins and other phenolic constituents, and preclinical work supports antioxidant activity. A 2002 animal study evaluated an emblicanin-enriched fraction and reported effects on oxidative-stress measures.

Human evidence remains indirect. In a 2013 randomised study involving people with type 2 diabetes, a standardised Phyllanthus emblica extract improved endothelial-function and oxidative-stress biomarkers over twelve weeks. That trial did not measure mitochondrial biogenesis, mitochondrial DNA damage, mitophagy, or “young” versus “aged” mitochondria.

Accordingly, Amalaki can accurately be discussed as a classical Rasayana ingredient with antioxidant and limited clinical biomarker evidence. It should not be advertised as a proven mitochondrial antioxidant therapy. Powder, fruit, juice, and extracts are not dose-equivalent, and honey or ghee is not suitable for everyone.

Ashwagandha: VO2 Max Is Not a Mitochondrial Biomarker

Aśvagandhā is identified in the Ayurvedic Pharmacopoeia as Withania somnifera Dunal. It is widely used in Ayurvedic practice for strength and restoration, but modern product extracts vary by plant part, extraction method, and withanolide profile. An eight-week study in elite Indian cyclists was published in 2012, while a 2015 trial involved healthy athletic adults over twelve weeks. Neither trial directly counted mitochondria or measured PGC-1α.

A 2020 systematic review selected five studies with 162 participants and concluded that ashwagandha might improve maximal oxygen uptake, while explicitly calling for further research. VO2 max is an integrated result of cardiac output, pulmonary function, blood oxygen transport, muscle perfusion, training status, motivation, and peripheral oxygen use. Improvement can be compatible with better metabolic performance, but it does not by itself demonstrate mitochondrial biogenesis.

There is therefore no verified basis for prescribing “300 mg twice daily for eight to twelve weeks” as a universal mitochondrial protocol or for claiming that ashwagandha and shilajit independently activate the same PGC-1α master switch in humans. Trial doses should remain attached to the exact extracts studied.

Guduchi: Animal Mitochondrial Findings and a Real Liver Warning

Guḍūcī, Tinospora cordifolia, appears in the classical Rasayana discussion, including among substances used for medhya purposes. Modern evidence does not verify that “tinospirone and cordycepin-like alkaloids” inhibit mTOR and induce human mitophagy. Cordycepin is characteristically associated with Cordyceps fungi, and no credible 2019 human immune-cell study matching the stated Guduchi claim was identified.

A relevant 2023 experiment used an ethanolic Tinospora cordifolia extract in rotenone-exposed mice. It reported changes in mitochondrial electron-transport-chain activity, membrane potential, oxidative stress, apoptosis-related proteins, and motor behaviour. That supports further preclinical investigation, not claims of human mitophagy, slower ageing, or Parkinson’s treatment.

Safety is especially important. LiverTox now regards Tinospora cordifolia as a well-established cause of clinically apparent liver injury, with reported cases ranging from enzyme elevations to severe hepatitis and acute liver failure, particularly in some people with pre-existing liver disease. This evidence rules out casual “400 mg daily” recommendations and argues strongly against unsupervised long-term use.

A Corrected Evidence Map

The following table separates classical placement, the strongest directly relevant modern evidence located, and what remains unproven. It is an evidence map, not a treatment protocol.

Material	Classical or pharmacopoeial basis	Most relevant modern evidence	Not established
Shilajit	Processed shilajatu described in Charaka’s Rasayana chapter	Rat mitochondrial-bioenergetics study; small human muscle studies	Human CoQ10 cycling, PGC-1α activation, anti-ageing efficacy
Amalaki	Major fruit in Charaka’s Rasayana formulations; API monograph	Preclinical antioxidant work; human endothelial and oxidative-stress biomarkers	Human mitochondrial rejuvenation or Nrf2 restoration of aged mitochondria
Ashwagandha	API monograph; traditional strength and restorative use	Small exercise trials and a limited VO2-max meta-analysis	Direct human mitochondrial biogenesis
Guduchi	Included in classical Rasayana discussion	Mouse evidence involving oxidative stress and mitochondrial function	Human mitophagy, mTOR-mediated longevity, or Parkinson’s treatment
Haritaki	Prominent in Charaka’s Rasayana chapter; API name Terminalia chebula Retz.	Laboratory research exists, but no verified human mitochondrial endpoint was identified here	A bedtime dose that reduces cellular senescence through NF-κB in humans

What the Research Still Does Not Show

There are not yet robust human trials showing that a classical Rasayana course increases mitochondrial DNA copy number, TFAM, muscle PGC-1α, respiratory capacity, or mitophagy while also improving clinically meaningful ageing outcomes. Performance, fatigue, antioxidant biomarkers, and gene-expression signals are not direct proof of mitochondrial renewal or longer life.

Lifestyle Foundations With Stronger Mitochondrial Evidence

Regular physical activity has substantially stronger human evidence for mitochondrial adaptation than any herb discussed here. A 2025 systematic review and meta-analysis found increased PGC-1α expression after endurance exercise, although study heterogeneity was high. Both continuous and interval training can contribute; intensity should reflect health and training status.

Exercise: Combine sustainable aerobic activity with resistance training rather than treating one heart-rate zone as a universal prescription.
Food and recovery: Adequate protein, micronutrients, energy intake, and recovery support training adaptation; severe restriction can impair it.
Sleep and regular timing: Consistent sleep and wake schedules support metabolic and circadian health, but the evidence does not justify claiming that mitochondrial repair “peaks” at a universal clock time.
Fasting and cold exposure: These remain active research areas. A fixed sixteen-hour fast or deliberate cold exposure should not be presented as necessary Rasayana care or as proven human mitophagy treatment.

The closer classical parallel is a disciplined regimen of food, routine, restraint, sleep, mental steadiness, and conduct. Even here, classical recommendations require interpretation for constitution, age, disease, climate, occupation, and contemporary medical needs.

Practical Safety and Consultation

Do not combine shilajit, Amalaki, ashwagandha, Guduchi, and Haritaki simply because each is called Rasayana in some context. Form, dose, vehicle, duration, indication, contraindications, and product quality matter. Ashwagandha can interact with medicines and is not advised in several situations, including pregnancy; rare liver injury has been reported. Guduchi has a clearer liver-injury signal. Mineral-containing or poorly controlled Ayurvedic products may also expose users to harmful heavy metals.

Research and safety note: The herb–mitochondria relationship is an evolving research field, not a validated anti-ageing protocol. Consult a qualified Ayurvedic practitioner and a healthcare professional before using Rasayana products, especially during pregnancy or breastfeeding, in children, with liver or kidney disease, autoimmune or thyroid disorders, before surgery, or while taking prescription medicines. Do not replace indicated medical treatment with these products.